Results 131 to 140 of about 15,755 (201)

Time and Resource Implications of Subcutaneous Daratumumab-Based versus Intravenous Isatuximab-Based Treatment Regimens for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible. [PDF]

Oncol Ther
Smith E, Camera A, Bird A.
europepmc   +1 more source

Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study. [PDF]

Ann Hematol
Wang Y, Chen X, Liang Q, Wang W, Luo J, Luo L, Feng R, Wei Y, Tian Y, Du X, Huang Z, Hu G, Fu X, Tao S, Zhou J, Peng H, Su Y, Zhang H, Dong M, Lan M, Sun Z, Wang X, Zhou H, Zhong L, Peter Gale R, Liang Y, Xia Z.   +26 more
europepmc   +1 more source

Impact of 1q vulnerabilities in patients treated with anti-CD38 monoclonal antibodies. [PDF]

Front Oncol
Sánchez-Tabernero M, Zamanillo I, Sánchez-Pina JM, Alonso-Fernandez R, López-Muñoz N, Corona M, Fernández-Guijarro M, Cedena MT, Cortijo S, Calbacho M, Martinez-Lopez J.   +10 more
europepmc   +1 more source

Exercise-mobilized lymphocytes enhance antibody-based immunotherapy in multiple myeloma through CD16⁺ NK cell-mediated cytotoxicity. [PDF]

J Transl Med
Chou L, Valenzuela AM, McDougal LM, Baker FL, Katsanis E, Simpson RJ.   +5 more
europepmc   +1 more source

Case Report: Dual impact of daratumumab in early T-cell precursor acute lymphoblastic leukemia -- consolidation therapy achieves remission and eliminates donor-specific HLA antibodies. [PDF]

Front Immunol
Wong KL, Tuy T, Quek J, Linn YC.
europepmc   +1 more source

Daratumumab in the Treatment of Multiple Myeloma: Real World Evidence (2018-2024) at the a. Gemelli Polyclinic (Rome) and Comparison With Registration Studies. [PDF]

Hosp Pharm
Favia M, Sperandeo M, Cerbo LD, Sabia A, Musicco F, Za T, Campopiano R, Rossi E, Pani M, Tarantino D.   +9 more
europepmc   +1 more source

A protocol for assessing the efficacy of pomalidomide in patients with relapsed and/or refractory multiple myeloma [PDF]

, 2015
Αναγνωστόπουλος, Ζαφείριος
core   +1 more source

Daratumumab inhibits acute myeloid leukemia metabolic capacity by blocking mitochondrial transfer from mesenchymal stromal cells [PDF]

, 2020
Bowles, Kristian M., Collins, Angela, Di Palma, Federica, Hellmich, Charlotte, Jibril, Aisha, Kumar, Prakritt, Marlein, Christopher R., Mistry, Jayna J., Moore, Jamie A., Pillinger, Genevra, Rushworth, Stuart A.   +10 more
core   +2 more sources

Daratumumab induced lichenoid drug eruption. [PDF]

JAAD Case Rep
Perz C, Wissman T, Montebello A.
europepmc   +1 more source

Treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with multiple myeloma: longer follow-up of the real-world MMY4032 study. [PDF]

Ann Hematol
Yang W, Wang L, Wang Y, Niu T, Fu R, Zhong Y, Qian W, Ding K, Sun K, Liu H, Fang B, Liu H, Li Y, Yang Y, Zhuo J, Chen X, Xun B, Lu J.   +17 more
europepmc   +1 more source